ATE505487T1 - Fvii- oder fviia-varianten mit erhöhter koagulationswirkung - Google Patents
Fvii- oder fviia-varianten mit erhöhter koagulationswirkungInfo
- Publication number
- ATE505487T1 ATE505487T1 AT03747838T AT03747838T ATE505487T1 AT E505487 T1 ATE505487 T1 AT E505487T1 AT 03747838 T AT03747838 T AT 03747838T AT 03747838 T AT03747838 T AT 03747838T AT E505487 T1 ATE505487 T1 AT E505487T1
- Authority
- AT
- Austria
- Prior art keywords
- fvii
- variants
- coagulation effect
- fviia variants
- increased coagulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41483602P | 2002-09-30 | 2002-09-30 | |
US47964203P | 2003-06-19 | 2003-06-19 | |
PCT/DK2003/000632 WO2004029091A2 (en) | 2002-09-30 | 2003-09-26 | FVII OR FVIIa VARIANTS HAVING INCREASED CLOTTING ACTIVITY |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE505487T1 true ATE505487T1 (de) | 2011-04-15 |
Family
ID=32045297
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03747838T ATE505487T1 (de) | 2002-09-30 | 2003-09-26 | Fvii- oder fviia-varianten mit erhöhter koagulationswirkung |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060166874A1 (de) |
EP (1) | EP1549677B1 (de) |
JP (1) | JP4472526B2 (de) |
AT (1) | ATE505487T1 (de) |
AU (2) | AU2003266931B2 (de) |
CA (2) | CA2840692A1 (de) |
DE (1) | DE60336741D1 (de) |
DK (1) | DK1549677T3 (de) |
WO (1) | WO2004029091A2 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247708B2 (en) | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
DK1257295T3 (da) | 2000-02-11 | 2009-08-10 | Bayer Healthcare Llc | Faktor VII eller VIIA-lignende molekyler |
US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7812132B2 (en) | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
RU2004134726A (ru) | 2002-04-30 | 2005-06-10 | Максиджен Холдингз Лтд. (Ky) | Варианты полипептида фактора vii или viia |
CA2519873C (en) | 2003-03-20 | 2012-12-18 | Maxygen Holdings Ltd. | Fvii or fviia variants |
MXPA05010773A (es) | 2003-04-09 | 2005-12-12 | Neose Technologies Inc | Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos. |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
ES2338425T3 (es) * | 2003-06-19 | 2010-05-07 | Bayer Healthcare Llc | Variantes de dominio de gla del factor vii o viia. |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
ATE547519T1 (de) | 2003-09-09 | 2012-03-15 | Novo Nordisk Healthcare Ag | Gerinnungsfaktor-vii-polypeptide |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
AU2004294403A1 (en) | 2003-12-01 | 2005-06-16 | Novo Nordisk Health Care Ag | Nanofiltration of factor VII solutions to remove virus |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
EP3378470A1 (de) | 2003-12-19 | 2018-09-26 | Novo Nordisk Health Care AG | Stabilisierte zusammensetzungen aus faktor-vii-polypeptiden |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
CN101006175A (zh) | 2004-08-17 | 2007-07-25 | Csl百灵有限公司 | 经修饰的维生素k依赖性多肽 |
JP2008514215A (ja) * | 2004-09-29 | 2008-05-08 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 改変タンパク質 |
JP5948627B2 (ja) | 2004-10-29 | 2016-07-20 | レイショファーム ゲーエムベーハー | 線維芽細胞成長因子(fgf)のリモデリングと糖質ペグ化 |
EP1831242B1 (de) | 2004-12-23 | 2012-09-26 | Novo Nordisk Health Care AG | Reduktion des gehaltes an kontaminierenden proteinen in zusammensetzungen, die vitamin k-abhängige proteine von interesse umfassen |
EP1858543B1 (de) | 2005-01-10 | 2013-11-27 | BioGeneriX AG | Glycopegylierten Granulocyten-Kolonie-stimulierender Faktor |
EP2386571B1 (de) | 2005-04-08 | 2016-06-01 | ratiopharm GmbH | Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons |
US20080188400A1 (en) * | 2005-04-26 | 2008-08-07 | Maxygen Holdings Ltd. | Methods For Treating Bleeding |
EP2975135A1 (de) | 2005-05-25 | 2016-01-20 | Novo Nordisk A/S | Glykopegylierter Faktor IX |
EP1893632B1 (de) | 2005-06-17 | 2015-08-12 | Novo Nordisk Health Care AG | Selektive reduktion und derivatisierung manipulierter faktor vii proteine mit mindestens einem nichtnativen zystein |
WO2007006808A1 (en) | 2005-07-13 | 2007-01-18 | Novo Nordisk Health Care Ag | Host cell protein knock-out cells for production of therapeutic proteins |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
JP5894722B2 (ja) | 2005-09-01 | 2016-03-30 | ノボ ノルディスク ヘルス ケア アーゲー | 第vii因子ポリペプチドの疎水性相互作用クロマトグラフィ精製 |
US20090055942A1 (en) * | 2005-09-14 | 2009-02-26 | Novo Nordisk Healthcare A/G | Human Coagulation Factor VII Polypeptides |
WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
JP5570809B2 (ja) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | 修飾タンパク質 |
JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | ポリペプチドコンジュゲートの精製方法 |
EP2114379A2 (de) * | 2006-12-20 | 2009-11-11 | Bayer HealthCare LLC | Faktor-vi- und -viia-zusammensetzungen |
EP1972687A1 (de) * | 2007-03-23 | 2008-09-24 | GenOdyssee | Polynukleotide und Polypeptide des menschlichen Faktor-VII-Gens, SNPs |
KR20150064246A (ko) | 2007-04-03 | 2015-06-10 | 바이오제너릭스 게엠베하 | 글리코페길화 g―csf를 이용하는 치료 방법 |
KR20100016462A (ko) | 2007-04-13 | 2010-02-12 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 변형 제vii 인자 폴리펩타이드 및 이의 용도 |
CA2690611C (en) | 2007-06-12 | 2015-12-08 | Novo Nordisk A/S | Improved process for the production of nucleotide sugars |
WO2009108806A1 (en) | 2008-02-27 | 2009-09-03 | Novo Nordisk A/S | Conjugated factor viii molecules |
TWI538916B (zh) * | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
WO2021102271A1 (en) * | 2019-11-22 | 2021-05-27 | Sigilon Therapeutics, Inc. | Monoclonal cell lines expressing an exogenous substance and uses thereof |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5258288A (en) * | 1986-07-25 | 1993-11-02 | Genzyme Corporation | Vector containing DNA encoding mature human protein S |
DK323587D0 (da) | 1987-06-25 | 1987-06-25 | Novo Industri As | Protein |
US5093317A (en) * | 1989-06-05 | 1992-03-03 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factor |
US5580560A (en) | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
ATE180834T1 (de) * | 1990-01-29 | 1999-06-15 | Zymogenetics Inc | Antikoagulierende proteine |
US5788965A (en) * | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
US5833982A (en) * | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
US5817788A (en) * | 1991-02-28 | 1998-10-06 | Zymogenetics, Inc. | Modified factor VII |
US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
JPH0720127A (ja) * | 1993-05-07 | 1995-01-24 | Eisai Co Ltd | 各種pivkaの測定方法および測定試薬 |
DE69429429T2 (de) * | 1993-05-21 | 2002-05-16 | Novo Nordisk A/S, Bagsvaerd | MODIFIZIERTER FAKTOR VII zur Hemmung der vaskulären Restenosis und Thrombozytenablagerung |
US5837843A (en) * | 1996-11-08 | 1998-11-17 | Oklahoma Medical Research Foundation | Modified protein C |
AU730133B2 (en) * | 1996-11-08 | 2001-02-22 | Oklahoma Medical Research Foundation | Modified protein C and methods of use thereof |
US6475725B1 (en) * | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US6747003B1 (en) * | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
DK1257295T3 (da) * | 2000-02-11 | 2009-08-10 | Bayer Healthcare Llc | Faktor VII eller VIIA-lignende molekyler |
US6423826B1 (en) * | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
RU2326126C2 (ru) * | 2000-09-13 | 2008-06-10 | Ново Нордиск Хелт Кэр Аг | Полипептид фактора vii свертывания крови, его получение и применение |
IL154880A0 (en) * | 2000-10-02 | 2003-10-31 | Novo Nordisk As | Method for the production of vitamin k-dependent proteins |
AU2002218029A1 (en) * | 2000-11-09 | 2002-05-21 | The Scripps Research Institute | Modified factor viia |
CA2470511C (en) | 2001-12-21 | 2014-05-27 | Novo Nordisk Health Care Ag | Liquid composition of factor vii polypeptides |
RU2004134726A (ru) * | 2002-04-30 | 2005-06-10 | Максиджен Холдингз Лтд. (Ky) | Варианты полипептида фактора vii или viia |
-
2003
- 2003-09-26 AT AT03747838T patent/ATE505487T1/de not_active IP Right Cessation
- 2003-09-26 JP JP2004538776A patent/JP4472526B2/ja not_active Expired - Fee Related
- 2003-09-26 DE DE60336741T patent/DE60336741D1/de not_active Expired - Lifetime
- 2003-09-26 CA CA2840692A patent/CA2840692A1/en not_active Abandoned
- 2003-09-26 EP EP03747838A patent/EP1549677B1/de not_active Expired - Lifetime
- 2003-09-26 US US10/529,624 patent/US20060166874A1/en not_active Abandoned
- 2003-09-26 WO PCT/DK2003/000632 patent/WO2004029091A2/en active Application Filing
- 2003-09-26 CA CA2502162A patent/CA2502162C/en not_active Expired - Fee Related
- 2003-09-26 DK DK03747838.5T patent/DK1549677T3/da active
- 2003-09-26 AU AU2003266931A patent/AU2003266931B2/en not_active Ceased
-
2010
- 2010-03-30 AU AU2010201266A patent/AU2010201266A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060166874A1 (en) | 2006-07-27 |
CA2840692A1 (en) | 2004-04-08 |
AU2010201266A1 (en) | 2010-04-22 |
AU2003266931A1 (en) | 2004-04-19 |
WO2004029091A2 (en) | 2004-04-08 |
JP2006517089A (ja) | 2006-07-20 |
CA2502162A1 (en) | 2004-04-08 |
EP1549677B1 (de) | 2011-04-13 |
AU2003266931B2 (en) | 2010-01-21 |
WO2004029091A3 (en) | 2004-05-21 |
JP4472526B2 (ja) | 2010-06-02 |
EP1549677A2 (de) | 2005-07-06 |
DE60336741D1 (de) | 2011-05-26 |
DK1549677T3 (da) | 2011-07-18 |
CA2502162C (en) | 2014-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60336741D1 (de) | FVII- ODER FVIIa-VARIANTEN MIT ERHÖHTER KOAGULATIONSWIRKUNG | |
WO2006114105A8 (en) | Use of modified factor vii for treating bleeding | |
ATE431403T1 (de) | Fvii oder fviia varianten | |
HUP0003077A2 (hu) | Módosított VII faktor | |
Czura et al. | Vagus nerve stimulation regulates hemostasis in swine | |
EE05419B1 (et) | Asendatud oksasolidinoonid kombineeritud raviks | |
BR0110659A (pt) | Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo | |
TR200103233T2 (tr) | Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri. | |
DK1066036T3 (da) | Midler med serotoninrelateret aktivitet til behandling af sövnapnö | |
DK1902141T3 (da) | ADAMTS 13-holdige sammensætninger med thrombolytisk virkning | |
CY1107054T1 (el) | Ενωσεις διτοσυλικου αλατος κιναζολινης | |
DE60315847D1 (de) | Varianten des menschliche koagulationsfaktors vii | |
WO2003100574A3 (en) | Dental appliances and systems and methods for distributing dental appliances | |
WO2007007098A3 (en) | Promotion of epithelial regeneration | |
HRP20050579B1 (hr) | Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol | |
SE0102147D0 (sv) | New methods | |
ATE435657T1 (de) | Therapeutische zubereitung von hochreinem fviia und verfahren zu dessen gewinnung | |
ATE539764T1 (de) | Verwendung mutierter antithrombine zur behandlung oder verhinderung von gerinnungserkrankungen | |
DE60214207D1 (de) | Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis | |
WO2004056768A3 (en) | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | |
DE60128009D1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
DE502006001740D1 (de) | Zusammensetzung zur Vorbeugung und Behandlung von Erkältungskrankheiten | |
DE50103012D1 (de) | Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen | |
TR200003502T2 (tr) | Bir Piperidin Maddesi P Antagonistini İçeren Mikroemülsiyon Prekonsantratları | |
PT862454E (pt) | Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |